Rare diseases
Investigational molecules
Locations
245 1st Street Suite 18, 02142-1292, United States
Tisento Therapeutics Inc. focuses on mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), with clinical activity centered on the treatment of this rare mitochondrial disorder and its neurological and systemic manifestations.
The sponsor’s research interest is directed toward clinical evaluation in patients affected by inherited energy metabolism dysfunction.
Tisento Therapeutics Inc. runs clinical trials in conditions such as MELAS syndrome, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Study on the Safety and Effectiveness of Zagociguat for Treating MELAS in Patients
GermanyLong-term safety study of zagociguat tablets in patients with MELAS syndrome (Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) who completed previous trial
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
